POLA1 and diffuse large B-cell lymphoma: A phase Ib study of glofitamab + Pola-R-CHP in untreated DLBCL demonstrated promising efficacy and tolerability [29], and the ongoing SKYGLO phase III trial is assessing this combination in a randomized setting [30].